References
- Schwab C, Harrison CJ. Advances in B-cell precursor acute lymphoblastic leukemia genomics. Hemasphere. 2018;2(4):e53.
- Fielding AK. Curing Ph + ALL: assessing the relative contributions of chemotherapy, TKIs, and allogeneic stem cell transplant. Hematol Am Soc Hematol Educ Program. 2019;2019(1):24–29.
- Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10(2):125–134.
- Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470–480.
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
- Chiaretti S, Messina M, Foà R. BCR/ABL1-like acute lymphoblastic leukemia: how to diagnose and treat? Cancer. 2019;125(2):194–204.
- Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012;22(2):153–166.
- Juric D, Lacayo NJ, Ramsey MC, et al. Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. J Clin Oncol. 2007;25(11):1341–1349.
- Borowitz MJ, Chan JKC, Downing J, et al. Precursor lymphoid neoplasms. In: Swerdlow SH, Campo E, Harris NL, editors. WHO classification of tumors of hematopoietic and lymphoid tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2017.
- Kadri S, Long BC, Mujacic I, et al. Clinical validation of a Next-Generation sequencing genomic oncology panel via Cross-Platform benchmarking against established amplicon sequencing assays. J Mol Diagn. 2017;19(1):43–56.
- Konoplev S, Lu X, Konopleva M, et al. CRLF2-Positive B-Cell acute lymphoblastic leukemia in adult patients: a Single-Institution experience. Am J Clin Pathol. 2017;147(4):357–363.
- Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005–1015.
- Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118(5):1208–1215.
- Soverini S, Branford S, Nicolini FE, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res. 2014;38(1):10–20.
- Yoda A, Yoda Y, Chiaretti S, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2010;107(1):252–257.
- Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009;9(12):874–885.
- Stroopinsky D, Kufe D, Avigan D. MUC1 in hematological malignancies. Leuk Lymphoma. 2016;57(11):2489–2498.
- Sadras T, Heatley SL, Kok CH, et al. Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions. Cancer Lett. 2017;408:92–101.
- Kawano T, Ito M, Raina D, et al. MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells. Cancer Res. 2007;67(24):11576–11584.
- Yap KL, Furtado LV, Kiyotani K, et al. Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL). Leuk Lymphoma. 2017;58(4):950–958.
- Mcneer J, Raca G, Gurbuxani S, et al. Use of chromosomal microarray analysis (CMA) to identify targetable mutations in acute lymphoblastic leukemia. Blood. 2014;124(21):5349–5349.
- Raca G, Gurbuxani S, Zhang Z, et al. RCSD1-ABL2 fusion resulting from a complex chromosomal rearrangement in high-risk B-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2015;56(4):1145–1147.